Arthritis News and Research

Latest Arthritis News and Research

Preventative measures to avoid Lyme disease

Research on the population of black-legged ticks, which can transmit Lyme disease from host animals to humans, reinforces that it is important to take preventative measures when spending time outdoors.

21 Jul 2010

Winston Laboratories receives NOC for CIVANEX

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its second quarter 2010 results.

20 Jul 2010

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Bioengineers from Rice University's BioScience Research Collaborative have won a $1.7 million grant from the National Institutes of Health to develop an injectable mix of polymers and adult stem cells that can spur the growth of new cartilage in injured knees and other joints.

20 Jul 2010

Amgen granted FDA priority review designation for denosumab BLA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

17 Jul 2010

Study shows high rate of return to pre-injury level of function with arthroscopic treatment

Athletes who undergo arthroscopic surgery for a mechanical disorder of the hip have a good chance of being able to return to their sport at a high level of competition, according to a study that will be presented at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, R.I. Almost 80 percent of patients were able to return to play after hip arthroscopy at an average of 9.4 months after surgery, and roughly 90 percent were able to return to the same level of competition.

16 Jul 2010

AAOS releases evidence-based clinical practice guideline for treating glenohumeral joint osteoarthritis

The American Academy of Orthopaedic Surgeons has approved and released an evidence-based clinical practice guideline on "The Treatment of Glenohumeral Joint Osteoarthritis." This major joint in the shoulder - the ball and socket joint - is sometimes affected by osteoarthritis, causing pain, loss of function, and reduced quality of life.

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

Ligand Pharmaceuticals announces launch of redesigned Web site

Ligand Pharmaceuticals Incorporated announces the launch of its completely redesigned Web site: www.ligand.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about Ligand's business model, robust pipeline, high-profile partnerships and innovative technology.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Hospital for Special Surgery named top hospital for orthopedics

Hospital for Special Surgery has been named the top hospital in the nation for orthopedics by U.S. News & World Report in its 2010 "America's Best Hospitals" issue. Once again the hospital ranked as a leader in rheumatology at number 3 in the nation. In addition, neurology was ranked at number 16.

15 Jul 2010

Mylan subsidiary receives FDA final approval for Nabumetone Tablets ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg.

15 Jul 2010

Susceptibility to Behcet's disease associated with genes involved in body's immune response

Researchers with the National Institutes of Health have found susceptibility to Behcet's disease, a painful, inflammatory condition, to be associated with genes involved in the body's immune response.

14 Jul 2010

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.

13 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.

12 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec and Swedish Orphan Biovitrum today announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data from a Phase 1/2a open-label, cross-over, multi-center, dose-escalation study that evaluated the safety and pharmacokinetics of an intravenous injection of rFVIIIFc in 16 previously-treated patients with severe hemophilia A.

12 Jul 2010

New food safety requirements for large-scale egg producers: FDA

The U.S. Food and Drug Administration says that as many as 79,000 illnesses and 30 deaths due to consumption of eggs contaminated with the bacterium Salmonella Enteritidis may be avoided each year with new food safety requirements for large-scale egg producers.

9 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

Arthritis News and Research

Latest Arthritis News and Research

Preventative measures to avoid Lyme disease

Winston Laboratories receives NOC for CIVANEX

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Amgen granted FDA priority review designation for denosumab BLA

Study shows high rate of return to pre-injury level of function with arthroscopic treatment

AAOS releases evidence-based clinical practice guideline for treating glenohumeral joint osteoarthritis

New findings on macrophage activation can facilitate development of early diagnosis tools

Ligand Pharmaceuticals announces launch of redesigned Web site

NIH awards MacroGenics $9.8 million grant for three projects

Plexxikon announces promising preclinical data of PLX3397

Hospital for Special Surgery named top hospital for orthopedics

Mylan subsidiary receives FDA final approval for Nabumetone Tablets ANDA

Susceptibility to Behcet's disease associated with genes involved in body's immune response

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

New food safety requirements for large-scale egg producers: FDA

Phase II trial results of TB-402 presented at International Congress on Thrombosis

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Arthritis News and Research

Latest Arthritis News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in